Pretreatment Level of Red Cell Distribution Width as a Prognostic Indicator for Survival in a Large Cohort Study of Male Laryngeal Squamous Carcinoma
Conclusion: Higher pretreatment RDW levels were demonstrated to be associated with poor clinical outcome in male LSCC patients and might be novel markers for patient stratification in LSCC management. Introduction Laryngeal cancer is one of the most common cancers of the head and neck, of which the estimated crude incidence and mortality rates in China were 1.86/100,000 and 1.01/100,000, respectively (1). This disease has a male predominance with a male-to-female ratio of 20 to 30:1 in China (2). The most commonly observed histological type of laryngeal cancer is laryngeal squamous cell cancer (LSCC), accounting for 95% of cases involving the stratified squamous epithelial lining of the larynx (3, 4). Despite improvements in diagnosis and treatment in the last four decades, there was an absence of a significant change in the 5-year overall survival (OS) rate for larynx cancer patients (5). Several prognostic factors have been identified to predict prognosis in LSCC patients, such as tumor size, histological subtype or grade, vascular invasion, and lymph node metastases. However, the majority of these factors can only be assessed after surgery. Although “omics”-based technology has enhanced our perception of possible risk factors, prognoses and/or responses to treatment biomarkers, the validation of novel molecular biomarkers is associated with high costs, time-consuming procedures, and laboratory efforts. Therefore, a simple, rapid, reliable, and cheap pret...
Publication date: Available online 19 September 2020Source: International Journal of Surgery Case ReportsAuthor(s): Gabriel Fridolin Hess, Katharina Glatz, Sacha I. Rothschild, Otto Kollmar, Savas Deniz Soysal, Daniel T. Boll, Raoul André Droeser, Robert Mechera
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Robert A. Nagourney, Steven Evans, Peter H. Tran, Adam J. Nagourney, Paul H. Sugarbaker
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Loek A.W. de Jong, Nielka P. van Erp, Philip R. de Reuver
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): W.J. Koemans, J.W. van Sandick, A.D.R. Huitema
CONCLUSION: Splenic fibrosis progresses along with advancement of PH. Cygb-expressing cells in the splenic cord possibly participate in this process through mechanisms including oxidative stress. PMID: 32945524 [PubMed - as supplied by publisher]
Authors: Teng M, Zhou S, Cai C, Lupien M, He HH Abstract Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesse...
Publication date: Available online 19 September 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Iris van ’t Erve, Marjolein J.E. Greuter, Karen Bolhuis, Daan C.L. Vessies, Alessandro Leal, Geraldine R. Vink, Daan van den Broek, Victor E. Velculescu, Cornelis J.A. Punt, Gerrit A. Meijer, Veerle M.H. Coupé, Remond J.A. Fijneman
Publication date: Available online 19 September 2020Source: Pathology - Research and PracticeAuthor(s): Nazila Fathi Maroufi, Nima Ashouri, Zohreh Mortezania, Zahra Ashoori, Vahid Vahedian, Mohammad Taher Amirzadeh-Iranaq, Amir Fattahi, Hamid Kazemzadeh, Mariano Bizzarri, Maryam Akbarzadeh, Hamid Reza Nejabati, Yousef Faridvand, Mohammad-Reza Rashidi, Mohammad Nouri
Publication date: September 2020Source: Human Pathology: Case Reports, Volume 21Author(s): Yuri Noda, Yuko Nakanishi, Ayaka Izui, Hiroyo Takahashi, Chiya Oshiro, Hideo Inaji, Masaru Yamasaki
Conclusion: A nisin-producing probiotic, can be used to treat 'disease-altered' biofilms and promote healthier oral biofilms, which may be useful for improving patient oral health. PMID: 32944159 [PubMed]
More News: Academia | Anemia | Autoimmune Disease | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | China Health | Diets | ENT & OMF | Epithelial Cancer | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Germany Health | Grants | Head and Neck Cancer | Heart | Hematology | Hypertension | Infectious Diseases | Kidney Cancer | Laboratory Medicine | Laryngeal Cancer | Laryngectomy | Lung Cancer | Medical Ethics | Nephrectomy | Non-Small Cell Lung Cancer | Nutrition | Oral Cancer | Oral Cavity Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Pathology | Pharyngeal Cancer | Prostate Cancer | Renal Cell Carcinoma | Reproduction Medicine | Science | Skin Cancer | Smokers | Spain Health | Squamous Cell Carcinoma | Statistics | Study | Switzerland Health | Thyroid | Thyroid Cancer | Women